BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 9700154)

  • 1. Growth factor-induced p42/p44 MAPK nuclear translocation and retention requires both MAPK activation and neosynthesis of nuclear anchoring proteins.
    Lenormand P; Brondello JM; Brunet A; Pouysségur J
    J Cell Biol; 1998 Aug; 142(3):625-33. PubMed ID: 9700154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The p42/p44 mitogen-activated protein kinase cascade is determinant in mediating activation of the Na+/H+ exchanger (NHE1 isoform) in response to growth factors.
    Bianchini L; L'Allemain G; Pouysségur J
    J Biol Chem; 1997 Jan; 272(1):271-9. PubMed ID: 8995258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway.
    Lavoie JN; L'Allemain G; Brunet A; Müller R; Pouysségur J
    J Biol Chem; 1996 Aug; 271(34):20608-16. PubMed ID: 8702807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PKC-dependent activation of p44/p42 MAPKs during myocardial ischemia-reperfusion in conscious rabbits.
    Ping P; Zhang J; Cao X; Li RC; Kong D; Tang XL; Qiu Y; Manchikalapudi S; Auchampach JA; Black RG; Bolli R
    Am J Physiol; 1999 May; 276(5):H1468-81. PubMed ID: 10330229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry.
    Brunet A; Roux D; Lenormand P; Dowd S; Keyse S; Pouysségur J
    EMBO J; 1999 Feb; 18(3):664-74. PubMed ID: 9927426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An anchorage-dependent signal distinct from p42/44 MAP kinase activation is required for cell cycle progression.
    Le Gall M; Grall D; Chambard JC; Pouysségur J; Van Obberghen-Schilling E
    Oncogene; 1998 Sep; 17(10):1271-7. PubMed ID: 9771970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet-derived-growth-factor stimulation of the p42/p44 mitogen-activated protein kinase pathway in airway smooth muscle: role of pertussis-toxin-sensitive G-proteins, c-Src tyrosine kinases and phosphoinositide 3-kinase.
    Conway AM; Rakhit S; Pyne S; Pyne NJ
    Biochem J; 1999 Jan; 337 ( Pt 2)(Pt 2):171-7. PubMed ID: 9882612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. G alpha(i-2) mediates renal LLC-PK1 growth by a Raf-independent activation of p42/p44 MAP kinase.
    Kinane TB; Kang I; Chu A; Chin SH; Ercolani L
    Am J Physiol; 1997 Feb; 272(2 Pt 2):F273-82. PubMed ID: 9124407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The thyrotropin receptor is not involved in the activation of p42/p44 mitogen-activated protein kinases by thyrotropin preparations in Chinese hamster ovary cells expressing the human thyrotropin receptor.
    Corrèze C; Blondeau JP; Pomerance M
    Thyroid; 2000 Sep; 10(9):747-52. PubMed ID: 11041451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts.
    Milanini J; Viñals F; Pouysségur J; Pagès G
    J Biol Chem; 1998 Jul; 273(29):18165-72. PubMed ID: 9660776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of tumor necrosis factor-induced p42/p44 mitogen-activated protein kinase activation by sodium salicylate.
    Schwenger P; Skolnik EY; Vilcek J
    J Biol Chem; 1996 Apr; 271(14):8089-94. PubMed ID: 8626494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nerve growth factor stimulation of p42/p44 mitogen-activated protein kinase in PC12 cells: role of G(i/o), G protein-coupled receptor kinase 2, beta-arrestin I, and endocytic processing.
    Rakhit S; Pyne S; Pyne NJ
    Mol Pharmacol; 2001 Jul; 60(1):63-70. PubMed ID: 11408601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of the p38 and p42/p44 mitogen-activated protein kinase families by the histamine H(1) receptor in DDT(1)MF-2 cells.
    Robinson AJ; Dickenson JM
    Br J Pharmacol; 2001 Aug; 133(8):1378-86. PubMed ID: 11498525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitogenic effect of oxidized low-density lipoprotein on vascular smooth muscle cells mediated by activation of Ras/Raf/MEK/MAPK pathway.
    Yang CM; Chien CS; Hsiao LD; Pan SL; Wang CC; Chiu CT; Lin CC
    Br J Pharmacol; 2001 Apr; 132(7):1531-41. PubMed ID: 11264247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p42/p44 mitogen-activated protein kinases activation is required for the insulin-like growth factor-I/insulin induced proliferation, but inhibits differentiation, in rat fetal brown adipocytes.
    Porras A; Alvarez AM; Valladares A; Benito M
    Mol Endocrinol; 1998 Jun; 12(6):825-34. PubMed ID: 9626658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling.
    Pouysségur J; Volmat V; Lenormand P
    Biochem Pharmacol; 2002 Sep; 64(5-6):755-63. PubMed ID: 12213567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nerve growth factor signaling involves interaction between the Trk A receptor and lysophosphatidate receptor 1 systems: nuclear translocation of the lysophosphatidate receptor 1 and Trk A receptors in pheochromocytoma 12 cells.
    Moughal NA; Waters C; Sambi B; Pyne S; Pyne NJ
    Cell Signal; 2004 Jan; 16(1):127-36. PubMed ID: 14607283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Studies on cell signaling immunomodulated murine peritoneal suppressor macrophages: LPS and PMA mediate the activation of RAF-1, MAPK p44 and MAPK p42 and p38 MAPK].
    Chang ZL; Lin MQ; Wang MZ; Yao Z
    Shi Yan Sheng Wu Xue Bao; 1997 Mar; 30(1):73-81. PubMed ID: 10684111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The nucleus, a site for signal termination by sequestration and inactivation of p42/p44 MAP kinases.
    Volmat V; Camps M; Arkinstall S; Pouysségur J; Lenormand P
    J Cell Sci; 2001 Oct; 114(Pt 19):3433-43. PubMed ID: 11682603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol.
    Knockaert M; Lenormand P; Gray N; Schultz P; Pouysségur J; Meijer L
    Oncogene; 2002 Sep; 21(42):6413-24. PubMed ID: 12226745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.